Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may significantly promote weight loss in obese patients with obstructive sleep apnea (OSA).

• GLP-1 RAs, such as liraglutide, semaglutide, and tirzepatide, are originally developed for type 2 diabetes but show promise in treating obesity-related conditions.
• These medications may improve OSA symptoms by decreasing fat around the upper airway and reducing systemic inflammation.
• Emerging clinical trials indicate that GLP-1 RAs could enhance traditional OSA treatments by addressing the metabolic issues contributing to the condition.
• GLP-1 RAs may also provide benefits for other obesity-related health issues, such as hypertension and cardiovascular disease, which are often seen in OSA patients.
• The integration of GLP-1 RAs into OSA management strategies could represent a significant shift toward more holistic treatment approaches.

AI simplified